Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evacetrapib - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Evacetrapib - Eli Lilly and Company

Alternative Names: LY-2484595

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperlipidaemics; Benzazepines; Carboxylic acids; Cyclohexanes; Small molecules; Tetrazoles
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in United Kingdom (IV, Infusion)
  • 30 Aug 2017 Efficacy data from the phase III ACCELERATE trial in Cardiovascular disorders presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
  • 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico due to insufficient efficacy and program termination (PO) (NCT02227784)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top